title: Position paper of the National Osteoporosis Foundation of South Africa (NOFSA) on the use of parathyroid hormone (PTH 1-34) in the treatment of osteoporosis.
authors.forename: Stephen
authors.initials: S
authors.lastname: Hough
authors.forename: Brynne
authors.initials: B
authors.lastname: Ascott-Evans
authors.forename: Tobie
authors.initials: T
authors.lastname: de Villiers
authors.forename: Jan
authors.initials: J
authors.lastname: de Weerd
authors.forename: Graham
authors.initials: G
authors.lastname: Ellis
authors.forename: Stan
authors.initials: S
authors.lastname: Lipschitz
mesh_terms: D000368:Aged; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D018579:Patient Selection; D011379:Prognosis; D018570:Risk Assessment; D013019:South Africa; D016896:Treatment Outcome
chemical_list: D010281:Parathyroid Hormone